Itsuro Shimada

597 total citations
19 papers, 490 citations indexed

About

Itsuro Shimada is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Organic Chemistry. According to data from OpenAlex, Itsuro Shimada has authored 19 papers receiving a total of 490 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Organic Chemistry. Recurrent topics in Itsuro Shimada's work include Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (5 papers) and Cancer therapeutics and mechanisms (4 papers). Itsuro Shimada is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (5 papers) and Cancer therapeutics and mechanisms (4 papers). Itsuro Shimada collaborates with scholars based in Japan, Norway and United States. Itsuro Shimada's co-authors include Yoko Ueno, Sadao Kuromitsu, Masamichi Mori, Rika Saito, Kenichi Mori, Ruriko Tanaka, Naoki Kaneko, Masaki Yamada, Yasuharu Kimura and Shuichi Sakamoto and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Itsuro Shimada

18 papers receiving 478 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Itsuro Shimada Japan 10 194 161 132 88 77 19 490
Alessandra Pannunzio Italy 12 169 0.9× 209 1.3× 86 0.7× 93 1.1× 16 0.2× 21 505
Kokichi Suzuki Japan 10 144 0.7× 71 0.4× 115 0.9× 86 1.0× 25 0.3× 15 399
Stephen T. Rapundalo United States 12 250 1.3× 55 0.3× 188 1.4× 23 0.3× 13 0.2× 21 560
Stephen M. Courtney United Kingdom 12 346 1.8× 46 0.3× 215 1.6× 95 1.1× 109 1.4× 15 572
Franziska Wachter United States 13 369 1.9× 70 0.4× 38 0.3× 157 1.8× 14 0.2× 28 521
Thorsten Gräf Germany 12 278 1.4× 177 1.1× 33 0.3× 113 1.3× 10 0.1× 16 528
Brian Metcalf United States 10 221 1.1× 30 0.2× 136 1.0× 84 1.0× 16 0.2× 18 578
Sushil Kumar Gupta India 10 181 0.9× 71 0.4× 116 0.9× 180 2.0× 34 0.4× 22 486
Tina Morgan Ross United States 9 453 2.3× 39 0.2× 140 1.1× 322 3.7× 37 0.5× 14 749
Jörn Weisner Germany 11 278 1.4× 23 0.1× 145 1.1× 63 0.7× 23 0.3× 20 426

Countries citing papers authored by Itsuro Shimada

Since Specialization
Citations

This map shows the geographic impact of Itsuro Shimada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Itsuro Shimada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Itsuro Shimada more than expected).

Fields of papers citing papers by Itsuro Shimada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Itsuro Shimada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Itsuro Shimada. The network helps show where Itsuro Shimada may publish in the future.

Co-authorship network of co-authors of Itsuro Shimada

This figure shows the co-authorship network connecting the top 25 collaborators of Itsuro Shimada. A scholar is included among the top collaborators of Itsuro Shimada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Itsuro Shimada. Itsuro Shimada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
3.
4.
Mori, Masamichi, Naoki Kaneko, Yoko Ueno, et al.. (2017). Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Investigational New Drugs. 35(5). 556–565. 200 indexed citations
5.
Hirakura, Yutaka, et al.. (2015). Characterization and Thermodynamic Stability of Polymorphs of Di(arylamino) Aryl Compound ASP3026. Chemical and Pharmaceutical Bulletin. 63(6). 418–422. 5 indexed citations
6.
Mori, Masamichi, Yoko Ueno, Hiroshi Fushiki, et al.. (2014). The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice. Molecular Cancer Therapeutics. 13(2). 329–340. 49 indexed citations
7.
Mori, Masamichi, Naoki Kaneko, Yoko Ueno, et al.. (2014). ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML).. Journal of Clinical Oncology. 32(15_suppl). 7070–7070. 24 indexed citations
8.
Ueno, Yoko, Naoki Kaneko, Rika Saito, et al.. (2014). ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in combination with cytarabine and anthracycline in acute myeloid leukemia (AML).. Journal of Clinical Oncology. 32(15_suppl). 7071–7071. 9 indexed citations
9.
Shimada, Itsuro, et al.. (2013). Atropisomeric 4-Phenyl-4H-1,2,4-triazoles as Selective Glycine Transporter 1 Inhibitors. Journal of Medicinal Chemistry. 56(14). 5744–5756. 24 indexed citations
10.
Fushiki, Hiroshi, Rika Saito, Makoto Jitsuoka, et al.. (2013). Abstract 2678: First demonstration of in vivo PET imaging for ALK inhibitor using [11C]ASP3026, a novel brain-permeable type of ALK inhibitor.. Cancer Research. 73(8_Supplement). 2678–2678. 2 indexed citations
11.
Fushiki, Hiroshi, Hideki Sakagami, Yoko Ueno, et al.. (2013). Abstract 918: ASP3026, a selective ALK inhibitor, shows anti-tumor activity in a mouse model xenografted with NCI-H2228 intracranially.. Cancer Research. 73(8_Supplement). 918–918. 1 indexed citations
12.
Mori, Masamichi, Sadao Kuromitsu, Yoko Ueno, et al.. (2012). Abstract 866: ASP3026, a selective ALK inhibitor, induces tumor regression in a crizotinib-refractory model and prolongs survival in an intrapleurally xenograft model. Cancer Research. 72(8_Supplement). 866–866. 7 indexed citations
13.
Shimada, Itsuro, et al.. (2012). Practical and efficient synthesis of the (R)-atropisomer of a 4-phenyl 1,2,4-triazole derivative as a selective GlyT1 inhibitor. Tetrahedron Asymmetry. 23(22-23). 1528–1533. 8 indexed citations
14.
Shimada, Itsuro, et al.. (2011). Synthesis and biological evaluation of (4H-1,2,4-triazol-4-yl)isoquinoline derivatives as selective glycine transporter 1 inhibitors. Bioorganic & Medicinal Chemistry. 20(1). 34–41. 4 indexed citations
15.
Kuromitsu, Sadao, Masamichi Mori, Itsuro Shimada, et al.. (2011). Abstract 2821: Anti-tumor activity of ASP3026, – A novel and selective ALK inhibitor -. Cancer Research. 71(8_Supplement). 2821–2821. 9 indexed citations
16.
Shimada, Itsuro, Takeshi Suzuki, Atsuyuki Kohara, et al.. (2010). Synthesis and Biological Evaluation of 3-Biphenyl-4-yl-4-phenyl-4H-1,2,4-triazoles as Novel Glycine Transporter 1 Inhibitors. Journal of Medicinal Chemistry. 54(1). 387–391. 35 indexed citations
17.
Shimada, Itsuro, Hidetaka Kaku, Keizo Sugasawa, et al.. (2007). Synthesis and structure–activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorganic & Medicinal Chemistry. 16(6). 3309–3320. 6 indexed citations
18.
Shimada, Itsuro, Kenichi Kazuta, Hideki Kubota, et al.. (2007). Synthesis and structure–activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists. Bioorganic & Medicinal Chemistry. 16(4). 1966–1982. 32 indexed citations
19.
Kimura, Yasuharu, et al.. (2003). Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist. European Journal of Pharmacology. 483(1). 37–43. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessandra Pannunzio Breakdown of academic impact, for papers by Kokichi Suzuki Breakdown of academic impact, for papers by Stephen T. Rapundalo Breakdown of academic impact, for papers by Stephen M. Courtney Breakdown of academic impact, for papers by Franziska Wachter Breakdown of academic impact, for papers by Thorsten Gräf Breakdown of academic impact, for papers by Brian Metcalf Breakdown of academic impact, for papers by Sushil Kumar Gupta Breakdown of academic impact, for papers by Tina Morgan Ross Breakdown of academic impact, for papers by Jörn Weisner
Rankless by CCL
2026